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Introduction
Epithelial ovarian cancer (EOC) is the second most
common gynecologic malignancy in Taiwan, with high
mortality due to the difficulty of early diagnosis. Stan-
dard treatment for advanced EOC is debulking surgery
followed by combination chemotherapy, usually a
platinum-based regimen. Although most patients ob-
tain a clinically complete or partial response with this
treatment, relapse is common and salvage chemother-
apy is often needed. In Taiwan, due to the rules of the
National Health Insurance, paclitaxel is usually reserved
as a second-line regimen for patients with relapsed di-
sease. Nevertheless, most disease progresses after a
short period of response to a paclitaxel-based regimen.
It is very challenging for a gynecologic oncologist to
treat a patient who is refractory to both platinum and
paclitaxel, because good treatment toleration with an
acceptable response is a major concern at this time. A
number of new agents are currently available with dem-
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onstrated activity in treating relapsed EOC. Among
these, pegylated liposomal doxorubicin (PLD) is one of
the most promising due to its tolerable toxicity.
PLD is a novel pegylated liposomal formulation of
the first-generation anthracycline doxorubicin. The
pharmacokinetics of this polyethylene-glycol-coated
liposome are characterized by a reduced volume of
distribution, a long intravascular circulating half-life,
and slow plasma clearance compared with free doxo-
rubicin [1]. This, coupled with the small vesicular size,
uniquely promotes the localization of PLD at tumor
sites and explains its altered toxicity profile [2]. Two
previous studies demonstrated a response rate of 18–
25% in patients with platinum- and/or paclitaxel-
refractory EOC receiving single-agent PLD [3,4].
However, no results are available regarding its effect
and toxicity in Asian populations.
Our purpose was to determine the anti-tumor activity
of PLD in Asian patients with both platinum- and
paclitaxel-refractory EOC at a single institute, and to
evaluate whether or not this activity is matched by low
toxicity in these heavily pretreated Asian patients.
Materials and Methods
The records of 18 patients with documented relapsed di-
sease, who had had prior treatment with both platinum-
and paclitaxel-based regimens within 6 months at
Kaohsiung Chang Gung Memorial Hospital, Taiwan,
were retrospectively reviewed between January 2000 and
December 2003. Our definitions for relapsed disease
were based on physical examination, histologic findings,
elevated levels of the tumor marker CA-125, and/or
positive imaging study. Patients were treated with PLD
40 mg/m2 intravenous infusion every 4 weeks until disease
progression or dose-limiting toxicity. Responding patients
were treated with a maximum of six cycles. All patients
who received one course of therapy were evaluated for
toxicity based on the National Cancer Institute Common
Toxicity Criteria. Anti-tumor responses were evaluated,
using the World Health Organization criteria, at every
course by physical examination, tumor markers and,
when indicated, imaging radiograms. Briefly, a complete
response was defined as complete disappearance of all
measurable and assessable disease for at least 1 month;
a partial response was documented in patients with a
greater than 50% decrease in the size of measurable
lesions for at least 1 month; stable disease was defined
as a reduction of less than 50% or an increase of less than
25% in the tumor lesion for at least 1 month; and
progressive disease was defined as an increase of more
than 25% in the tumor lesion compared with the status
before treatment. Changes in the levels of CA-125 were
also included in the definitions of response. The duration
of response was defined as the time from the onset of a
response until objective evidence of progressive disease.
Progression-free survival and overall survival curves were
calculated using the Kaplan-Meier technique.
Results
The mean age of the 18 patients was 51.6 years (range,
42–77 years). Twelve patients (66.7%) had serous EOC,
two (11.1%) had mucinous EOC, two (11.1%) had en-
dometrioid EOC, and two (11.1%) had undifferenti-
ated EOC (Table 1). Eleven patients had previous
chemotherapy with cisplatin plus cyclophosphamide
followed by taxol plus cisplatin/carboplatin, five patients
had previous chemotherapy with cisplatin/carboplatin
plus taxol, and two patients had previous chemotherapy
with cisplatin/carboplatin plus taxol followed by single-
agent topotecan. All 18 patients had elevated CA-125
(mean, 481 U/mL) before the initiation of PLD. Sixteen
patients had a measurable tumor on computed tomo-
graphy (CT) scan (including carcinomatosis, pelvic en-
larged node, bilateral inguinal enlarged nodes, skin
metastasis, pelvic tumor, liver surface nodules, pelvic
bone destruction, and lung nodules). Two patients had
a normal CT scan but a positive second-look laparotomy.
All 18 patients were assessable for response and
toxicity. Five patients (27.8%) experienced a response (3
complete responses, 2 partial responses) on the basis of
CA-125 level and/or CT scan. Four patients (22.2%)
had stable disease, while nine patients (50.0%) had
progressive disease. The median progression-free survival
was 14 weeks. Median survival was 48 weeks. Progres-
sion-free survival and overall survival (time to death)
curves are shown in Figures 1 and 2, respectively. Eight
patients experienced leukopenia, one patient developed
thrombocytopenia, and five patients developed anemia
(Table 2). There was no grade 3 or 4 leukopenia, throm-
bocytopenia, or anemia. One patient experienced
palmar-plantar erythrodysesthesia (PPE) and three
patients experienced stomatitis. Two patients (11.1%)
experienced severe skin pigmentation. There was no
treatment delay due to toxicity and there was no drug-
related fatal event. Ten patients completed six courses
of PLD, while the remaining eight patients received a
median of three courses (range, 2–5).
Discussion
A number of studies have investigated the efficacy of
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PLD in the treatment of refractory EOC. Muggia et al
reported a phase II study in 35 platinum- and paclitaxel-
refractory patients [3]. They used 50 mg/m2 every 3
weeks as the initial dose; however, about one-third of
patients experienced grade 3 or 4 non-hematologic
toxicities that required dose reductions or delays. In
their study, a response rate of about 25% was observed.
Gordon et al carried out another phase II study to as-
sess the effects of PLD in 82 patients who were platinum
and paclitaxel refractory [4]. PLD was administered at
50 mg/m2 every 4 weeks. In their study, the response
rate was 18.3%; however, 11.2% of patients experi-
enced significant adverse effects that required dose re-
ductions and delays. In the present single-institution
study, PLD at a dose of 40 mg/m2 every 4 weeks provided
a response rate of 27.8% and a modest percentage of
stable disease (22.2%), which is similar to the results
from Western countries. The dosage of PLD in our study
Table 1. Patient characteristics
Age
Histology Previous C/T Status before PLD
Cumulative Pre-tx Post-tx
Response Status
(yr) PLD dose CA-125 CA-125
77 Serous PC × 6, PT × 6 Right pelvic nodule 240 mg/m2 48.2 43.8 SD NED*
42 Serous PT × 6, Topo × 6 Bilateral inguinal LNs, 240 mg/m2 718 1,219 PD DOD
   skin metastasis
63 Serous PT × 6 Carcinomatosis 240 mg/m2 754 75 PR AWD
46 Endometrioid PT × 6 Right pelvic LN 240 mg/m2 73.8 21 CR NED*
46 Serous PC × 6, PT × 6 Liver capsule nodules 200 mg/m2 35 91.2 PD AWD
48 Undifferentiated PC × 6, PT × 6 Pelvic bone metastasis 240 mg/m2 289 331 SD AWD
54 Serous PC × 6, PT × 6 Carcinomatosis 240 mg/m2 623 201 PR DOD
47 Serous PC × 6, PT × 6, Positive 2nd look 200 mg/m2 276 474 PD DOD
   Topo × 6
53 Mucinous PC × 6, PT × 6 Carcinomatosis 120 mg/m2 694 929 PD DOD
47 Serous PT × 6 Positive 2nd look 240 mg/m2 39 46.9 SD AWD
42 Serous PC × 6, PT × 6 Carcinomatosis 240 mg/m2 858 19.7 CR DOD
47 Serous PC × 6, PT × 6 Carcinomatosis 240 mg/m2 537 15 CR NED
50 Endometrioid PT × 6 Carcinomatosis 180 mg/m2 443 1,523 PD AWD
53 Serous PC × 6, PT × 6 Carcinomatosis 160 mg/m2 961 2,429 PD AWD
45 Serous PC × 6, PT × 6 Lung nodules 240 mg/m2 527 231 SD AWD
50 Mucinous PT × 6 Carcinomatosis 180 mg/m2 58.6 342 PD DOD
53 Undifferentiated PT × 6 Carcinomatosis, liver, 180 mg/m2 258 317 PD DOD
   spleen metastases 1
66 Serous PC × 6, PT × 6 Carcinomatosis 200 mg/m2 1,470 2,226 PD AWD
C/T = chemotherapy; PLD = pegylated liposomal doxorubicin; Pre-tx = pretreatment; Post-tx = post-treatment; P = platinum; C = cyclophosphamide; T = taxol;
SD = stable disease; NED = no evidence of disease; Topo = topotecan; LN = lymph node; PD = progressive disease; DOD = died of disease; PR = partial response;
AWD = alive with disease; CR = complete response. *These 2 patients received further radiotherapy after PLD failure; both achieved CR.
Figure 2. Kaplan-Meier curve of overall survival. Curve is based
on Kaplan-Meier estimates. PLD = pegylated liposomal
doxorubicin.
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Figure 1. Kaplan-Meier curve of progression-free survival.
Curve is based on Kaplan-Meier estimates. PLD = pegylated
liposomal doxorubicin.
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Table 2. Adverse events
All grades, n (%)
   Grade
1 2 3 4
Leukopenia 8 (44.4) 7 1 0 0
Thrombocytopenia 1 (5.6)1 1 0 0 0
Anemia 5 (27.8) 1 4 0 0
Stomatitis 3 (16.7) 3 0 0 0
PPE 1 (5.6)1 0 1 0 0
PPE = palmar-plantar erythrodysesthesia.
was slightly lower than the recommended dose. The rea-
son for choosing 40 mg/m2 instead of 45 or 50 mg/m2
was that we believed there might be potential differ-
ences in chemotherapy-related toxicities between West-
ern and Asian populations. Furthermore, Rose et al
concluded that PLD at a dose of 40 mg/m2 every 4
weeks appeared to be as effective as 50 mg/m2 and was
better tolerated [5]. With this adjustment in dosage,
we achieved acceptable response and complication
rates. In our study, none of our heavily pretreated pa-
tients withdrew because of adverse events related to the
drug. However, the response duration in our study was
quite short. The median progression-free period was 14
weeks, versus 16–20 weeks in previous studies [4–6].
The most probable reason for shorter response duration
might be the inadequate treatment course, but not
the dosage. PLD actually increases the accumulated
dose of conventional free doxorubicin and reduces the
accumulated cardiotoxicity, thus greatly improving
the therapeutic window for doxorubicin. Therefore,
cumulative doses of PLD in excess of 500 mg/m2 appear
to carry a considerably lower risk of cardiomyopathy
than is generally associated with free doxorubicin [7].
Prolonged treatment with more than six courses of PLD
may have some benefits in improving patient survival.
Changes in the left ventricular ejection fraction and
clinical cardiac status must be carefully monitored as
the cumulative dose of PLD increases.
A lower incidence and fewer types of side effects are
directly attributed to PLD. The most common side
effects during PLD treatment tend to be non-hemato-
logic, including stomatitis and PPE. PPE (also called
hand-foot syndrome) is a cutaneous reaction typically
involving the palms of the hands and soles of the feet.
Patients may experience paresthesia of the extremities,
followed by pain, edema, and erythema of the skin.
Discontinuation of the agent results in desquamation in
the affected area followed by re-epithelialization. The
incidence of PPE of at least grade 3, as assessed by
previous investigators at a dosage of 50 mg/m2 every
4 weeks, is reported as around 10–23% [4–6]. Dose
reduction can prevent the occurrence of PPE. In our
study, only one patient (5.6%) experienced grade 2
PPE. The relatively low rate and low grade of PPE can
be explained by the low-dose PLD administration.
Another bothersome, but not life-threatening, side ef-
fect was skin pigmentation change. Few reports have
mentioned the actual incidence of this event. Almost
all of our patients experienced a varying degree of
skin pigmentation change. Two (11.1%) were deeply
affected psychologically by severe skin pigmentation
change, although no physiologic injury occurred.
Discontinuation of PLD cannot reverse the pigmenta-
tion change. Therefore, careful counseling of patients
regarding this event is very important before initiation
of PLD.
In conclusion, PLD at a dose of 40 mg/m2 every 4
weeks was generally well tolerated and effective, even for
a heavily pretreated Asian population. Prolongation of
treatment time with more than six courses might improve
patient survival. This drug should be included in our
health insurance coverage against refractory ovarian
cancer, and most importantly should be offered without
any limitation (especially in terms of treatment course).
Our results may also provide some information for
further clinical trials on integrating PLD with other
agents for treatment of this catastrophic disease.
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